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Abstract 
Introduction: Long-term levodopa treatment of Parkinson’s disease (PD) is frequently 
complicated by spontaneously occurring involuntary muscle movements called 
dyskinesia. The exact pathological mechanism of this complication has not yet been 
elucidated. We have previously demonstrated that in PD patients the vulnerability to 
develop peripheral but not orofacial dyskinesia is associated with the presence of two 
variants of the GRIN2A gene. Moreover, we have shown that in tardive dyskinesia 
(TD) orofacial dyskinesia is associated with other polymorphisms as compared with 
peripheral dyskinesia. In the present study we investigate whether the peripheral 
versus orofacial nature of levodopa-induced dyskinesia (LID) in PD can be explained 
by considering polymorphisms for dopaminergic and serotonergic receptors. 
 
Materials and Methods: 101 Russian patients with PD (38M/63F) were examined. 
Genotyping was carried out on 19 SNPs for 3 neurotransmitter genes: 10 SNPs for 
DRD3 gene (rs11721264, rs167770, rs3773678, rs963468, rs7633291, rs2134655, 
rs9817063, rs324035, rs1800828, rs167771), 1 SNP for DRD4 gene (rs3758653), and 8 
SNPs for HTR2C gene (rs6318, rs5946189, rs569959, rs17326429, rs4911871, 
rs3813929, rs1801412, rs12858300). 
  
Results: Genotyping patients with PD and LID revealed that only rs3773678 (DRD3, 
dominant, p = 0.042) was associated with orofacial dyskinesia. 
 
Conclusion: The findings of the current study are not related to LID in PD itself, but to 
other forms of orofacial dyskinesia in this patient group. 
 
Abbreviations: PD – Parkinson’s disease; TD – Tardive dyskinesia; LID – Levodopa-
induced dyskinesia; MSN – Medium Spiny Neuron; NMDA – N-methyl-D-aspartate;  
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Introduction  
More than 45 years after its introduction levodopa still 
remains one of the most effective treatments for 
Parkinson’s disease (PD). However, long-term 
levodopa treatment of PD is frequently complicated 
by motor fluctuations and dyskinesia (Thanvi and Lo, 
2004; Thanvi et al., 2007; Del Sorbo and Albanese, 
2008). Several theories have been developed to 
explain the pathophysiology of this important 
treatment complication with the ultimate goal to 
develop treatments to prevent this side effect (Huot et 
al., 2013; Bargiotas and Konitsiotis, 2013; Cerasa et 
al., 2014). However, the exact pathological 
mechanism has not yet been elucidated.  
Recently, we reported our serendipitous finding in a 
small group of patients we used as a control group in 
our study on tardive dyskinesia (TD) in patients with 
schizophrenia, that two variants of GRIN2A gene 
were strongly associated with levodopa-induced 
dyskinesia (LID) and not with TD (Ivanova et al., 
2012; Loonen and Ivanova, 2013). It is important to 
note that these variants were already known to be 
associated with the age of onset of symptoms in 
patients suffering from Huntington’s disease (Arning 
et al., 2007). The GRIN2A gene encodes for a protein 
which is part of the ionotropic glutamatergic N-
methyl-D-aspartate (NMDA) receptor. As in 
Huntington’s disease (HD), motor symptoms are 
linked to NMDA receptor-induced excitotoxicity in 
striatal medium spiny neurons (MSNs) of the indirect 
pathway, we propose that the same mechanism 
causing dyskinesia in LID.   
Like hyperkinesia in HD (Sturrock and Leavitt, 2010), 
LID is also predominantly peripherally localized 
(Thanvi and Lo, 2004; Del Sorbo and Albanese, 
2008). TD is characterized by both peripheral and 
orofacial dyskinesia, the latter being more prevalent 
in most patients. We have previously demonstrated 
that in PD patients the vulnerability to develop 
peripheral but not orofacial dyskinesia is associated 
with the presence of two variants of the GRIN2A 
gene (Ivanova et al., 2012). Moreover, we found that 
these genes were not associated with the likelihood 
of developing TD. We have demonstrated in the past 
that in TD orofacial dyskinesia is associated with 
other single nucleotide polymorphisms (SNPs) than 
peripheral dyskinesia (Al Hadithy et al., 2009; Al 
Hadithy et al., 2010). During the present study, we 
investigate whether this peripheral versus orofacial 
nature of LID in PD can be explained by considering 
SNPs for dopaminergic and serotonergic receptor 
genes, as a potential mechanism. 
Materials and methods  
Ethics Statement 
The protocol was approved by the standing 
Institutional Review Board (Local Ethics Committee at 
the Siberian State Medical University, Tomsk, 
Russian Federation). Written informed consent was 
obtained from each patient.  None of the participants 
had a compromised capacity/ability to consent; 
hence, obtaining consent from the next-of-kin was not 
necessary and not recommended by the Local Ethics 
Committee. The work described in this article was 
carried out in accordance with The Code of Ethics of 
the World Medical Association (Declaration of 
Helsinki 1975, revised Fortaleza, Brazil, October 
2013) for experiments involving humans.   
  
Patients 
The patients included in this study were retrieved 
from the Department of Neurology and Neurosurgery 
of the Siberian State Medical University (SSMU), 
Tomsk, Siberia, Russian Federation. Included were 
neurological patients who were suffering from 
dyskinesia and corresponding patients without 
dyskinesia having the same diagnosis (usually PD). 
In order to categorize patients accurately a clinical 
diagnosis protocol of PD was applied according to 
ICD-10 (G20) and the international clinical diagnostic 
criteria of the Parkinson's UK Brain Bank of the PD 
Society of the United Kingdom (Hughes et al., 1992). 
The severity of Parkinson's disease was determined 
by utilizing the Unified Parkinson's Disease Rating 
Scale - UPDRS (Fahn et al., 1987) in the optimal “on” 
state. The stage of the disease was assessed using 
the "Hoehn and Yahr" scale (Hoehn and Jahr, 1967). 
The degree of movement disorders (hypokinesia, 
rigidity and resting tremor) was defined according to 
the section III of UPDRS scale, dedicated to 
movement disorders. The severity of dyskinesia was 
assessed according to the Abnormal Involuntary 
Movement Scale (AIMS) (Loonen and Van Praag, 
2007). This scale consists of 12 items, of which 7 are 
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severity. Each item is evaluated according to the 
following points: 0 - no violation; 1 - minimum 
disruption; 2 - mild disorders; 3 - moderately 
expressed disturbances; 4 - strongly expressed 
violations. The AIMS scores were transformed into a 
binary variable (presence or absence of dyskinesia) 
with internationally accepted Schooler and Kane’s 
criteria (Schooler and Kane, 1982) according to 
which, for making a definite diagnosis of the TD, 3 
points for one of the items or 2 points for at least 2 
items are required. This scale was applied during the 
‘on’ phase in levodopa-induced dyskinesia. Exclusion 
criteria were: non-Caucasian physical appearance 
(e.g., Mongoloid, Buryats, or Khakassians), inability 
to walk unsupported, delirium, amnesia; 
schizophrenia or schizoaffective disorder, acute 
myocardial infarction, hypertension IIb-III, severe 
forms of diabetes; acute infections; exacerbation of 
chronic diseases.  
Of the 143 Siberian patients examined 101 were 
diagnosed with PD, 21 patients with essential tremor 
and 21 with different forms of dystonia.  Fifty of them 
(35%) were males and 93 (65%) females and their 
mean age was 63.6 ± 11.9 (from 22 to 86 years). The 
age of patients with PD (38M/63F) varied from 44 to 
82 years. The age of onset of the PD was 59.7 ± 8.5 
years. The mean age of patients with PD was 66.0 ± 
7.9 years and the average duration of illness was 6.4 
± 4.5 years.   
45.7% of patients had complaints of unintended 
movements. In 74.4% of patients, abnormal 
movements were registered in the neck, shoulders 
and hips (e.g., twisting, swinging, pivoting motion, 
rotation hips in a circle); 62.8% of the patients had 
movements in the upper limbs, 60.5% of the patients 
had movements in the lower limbs. Disability was 
observed in 65.1% of patients with levodopa-induced 
dyskinesia. Only 58.1% of patients with unintentional 
movements realized the presence of abnormal 
movements.  
Apart from physical examination and assessment, a 
blood sample was taken for DNA isolation and 
genotyping. All genotyping was performed blind to the 
patients’ clinical status. 
 
DNA analysis 
DNA extraction and the Veracode Assay were 
conducted according to standard protocols (Ivanova 
et al., 2012). We selected a subset of 19 informative 
SNPs, or tag SNPs, that would accurately represent 
the majority of SNPs for 3 neurotransmitter genes: 10 
SNPs for DRD3 gene (rs11721264, rs167770, 
rs3773678, rs963468, rs7633291, rs2134655, 
rs9817063, rs324035, rs1800828, rs167771), 1 SNP 
for DRD4 gene (rs3758653), and 8 SNPs for HTR2C 
gene (rs6318, rs5946189, rs569959, rs17326429, 
rs4911871, rs3813929, rs1801412, rs12858300).  
The selection method was previously described by 
Xu and Taylor (freely available at 
http://www.niehs.nih.gov/snpinfo).  We selected only 
tag SNPs that captured at least 10 SNPs.   
 
Statistical analysis 
After having developed different strategies to account 
for missing data and interactions between different 
SNPs, classical logistic regression and a log-linear 
regression approach were used to analyze the data.  
The genotype prevalence was calculated separately 
in patients with and without dyskinesia to define the 
percentage of missing genotypes. The Hardy-
Weinberg equilibrium test was applied with Fisher’s 
exact test to groups. For the SNPs in the X-
chromosomal HTR2C gene, deviation from HWE was 
not calculated. One SNP for HTR2C gene, 
rs12858300, was monomorphic; therefore, it was 
included analysis. 
To analyze associations between the SNPs and the 
phenotypes, we used logistic regression for binary 
response traits and log-linear regression for 
continuous traits.  
The following genetic models were tested: 
1. Co-dominant; both alleles of a SNP influenced the 
phenotype 
2. Dominant; rare allele homo- and heterozygotes 
were tested against common allele homozygotes. 
3. Recessive; common allele homo- and 
heterozygotes were tested against rare allele 
homozygotes. 
4. Over-dominant; heterozygotes were tested against 
both homozygote alleles. 
5. Log-additive; a trend test for the genotypes, similar 
to the allele model, but comparisons were made 
among subjects (N) instead of chromosomes (2N). 
The test and estimates were based on a logistic 
regression model that coded the genotypes as 0, 1, 
or 2 to reflect the number of minor alleles. 
The statistical significance of a SNP was established 
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a polymorphism with the null model. Age, sex, and 
duration of disease were included into the models as 
covariates. The Akaike information criterion was 
applied to identify the model that best fits the data. 
SNP effects were quantified with the odds ratio (OR) 
and 95% confidence intervals. In the result tables, an 
OR for a log-additive model corresponds to an 
association between a rare allele and the presence of 
dyskinesia. The ORs for other models correspond to 
associations between the presence of dyskinesia and 
rare allele homo- and heterozygotes (Dominant), 
common allele homo- or heterozygotes (Recessive), 
or heterozygotes (Over-dominant).  
For the statistical analysis, we used both qualitative 
traits (represented by the existence or absence of 
dyskinesia) and quantitative traits (the severity of 
dyskinesia represented by the sum of the AIMS 
scores). Separately, the calculations for the total 
dyskinesia and its subtypes: orofacial and limb-
truncal were done. Therefore, the following 
phenotypes were analyzed. 
1. Levodopa-induced dyskinesia (Schooler-Kane 
criteria): 
      а. Orofacial LID (AIMS 1-4); 
      b. Limb-truncal LID (AIMS 5-7); 
      с. Orofacial and limb-truncal LID (AIMS 1-7). 
2. The severity of dyskinesia; total score for 1-4, 5-7, 
and 1-7. 
Dyskinesia was considered a qualitative trait 
(present/absent), but the degree of dyskinesia 
expression was analyzed as a quantitative trait. To 
avoid 0 values, 1 was added to the dyskinesia 
expression values, and then they were log2-
transformed to obtain a log-normal distribution. 
The statistical power was estimated based on the 
prevalence of the tested phenotypes in the Siberian 
sample and assumptions of a complete penetrance 
and disease allele prevalence of 0.2-0.3. For orofacial 
dyskinesia, to detect associations under different 
genetic models with OR of 1.5, 2.0, and 2.5, the 
power estimates varied between 14%-50%, 44%-
94%, and 78%-99%, respectively. For limb-truncal 
dyskinesia, the power estimates varied between 
10%-31%, 27%-75%, and 53%-95%, respectively. 
For either type of dyskinesia, the power estimates 
varied between 18%-65%, 58%-99%, and 91%-99%. 
Overall, it would be fair to say, that our study was 
reasonably powered to detect associations with OR, 
as little as 2.0. 
Results  
First, the Hardy-Weinberg equilibrium test was 
applied to analyze the frequency distribution of 
investigated polymorphisms. One SNP of HTR2C 
gene, rs12858300, was monomorphic; therefore, it 
was removed from further analysis. The Hardy-
Weinberg equilibrium in patients was observed for the 
following polymorphisms: rs3758653 (p = 0.894691), 
rs2134655 (p = 0.562467), rs324035 (p = 1), 
rs3773678 (p = 0.125774), rs167770 (p = 0.067768), 
rs167771 (p = 0.397278), rs7633291 (p = 1), 
rs1800828 (p = 0.795681). The Hardy-Weinberg 
equilibrium was not calculated for polymorphic 
variants rs6318, rs5946189, rs569959, rs17326429, 
rs4911871, rs3813929, rs1801412, rs12858300 due 
to the fact that the serotonin receptor gene HTR2C is 
located on the X-chromosome. 
The next step of the statistical analysis was 
calculation of the best genetic models based on 
Akaike information criterion (AIC); the log-additive 
model is presented only in the case of statistical 
significance. The correction for multiple comparisons 
was not yet applied.  
An association was found between presence or 
absence of orofacial dyskinesia (according to the 
Schooler-Kane criteria) and two investigated 
polymorphisms in all 143 neurological patients: 
rs3758653 (DRD4, Log-additive, Odds Ratio 
(OR)=2.31 [95%CI=1.10-4.87], p=0.032) and 
rs4911871 (HTR2C, dominant, OR=2.88 [1.03 – 
8.05], p=0.041. These polymorphic variants, in 
addition to a marker rs2134655 (DRD3, recessive 
p=0.040), are associated with dyskinesia and are 
represented as a quantitative indicator according to 
the sum of features from 1 to 4. 
None of the studied polymorphisms was significantly 
associated with qualitatively assessed limb-truncal 
dyskinesia with the exception of rs963468 (DRD3, 
dominant, p=0.034 based on the quantitative 
measures (table 1).  Discovering this polymorphism 
cannot help in calculating odds ratio, since all 11 
patients with dyskinesia possessed G/G genotype. 
When only the 101 patients suffering of Parkinson’s 
disease (PD) are considered, the results are even 
less convincing. Only rs3773678 (DRD3, dominant, 
p=0.042) was associated with orofacial dyskinesia. 
No significant associations were found with respect to 
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dyskinesia in this more limited, but pathologically 
more homogenous patient group. 
Discussion 
The results were inconsistent between the extended 
(N = 143) and limited (N = 101) patient populations.  
The following methodological problems may explain 
these differences: multiple testing of DRD3 and 
HTR2C polymorphisms, diagnostic heterogeneity, 
and poor clinical diagnosis of dyskinesia in 
comparison to other movement disorders using the 
AIMS. However, we previously established a strong 
relationship with two polymorphisms of the GRIN2A 
gene and dyskinesia in the same patient population 
and with the same study design (Ivanova et al., 
2012). In that study the association increased when 
we limited the extended population to the patients 
with PD. Therefore, it could be concluded that the 
currently described associations probably do not 
have a great clinical relevance. 
A feature of our study is the separation of dyskinesia 
into two variants which phenotypically differ from 
each other and according to our hypothesis may have 
a different genetic background. The sum of the first 
four parameters on the scale was used for AIMS 
assessment of orofacial dyskinesia (these 
parameters include facial expressions and mouth 
area), the sum of 5-7 parameters correspond to the 
expression of limb-truncal dyskinesia (movement of 
the limbs and trunk). We have previously found that 
orofacial tardive dyskinesia is associated with other 
polymorphisms than peripheral ones (Al Hadithy et 
al., 2009; Al Hadithy et al., 2010). A peculiar finding is 
that such associations are more prominent with 
respect to orofacial dyskinesia. The association we 
have previously found for LID with GRIN2A 
polymorphisms was limited to limb-truncal 
movements (Ivanova et al., 2012). These 
polymorphisms are also known to be associated with 
the age of onset of Huntington’s disease. The motor 
deficiency manifestations in HD are also localized in 
the limbs and trunk. This is another reason to believe, 
that the findings of the current study are not so much 
related to LID in PD, but to other orofacial dyskinesia 
in this patient group. Dyskinesia is known to occur 
spontaneously, particularly in elderly patients and 
patients with poorly fitted dentures (Woerner et al., 
1991). Both essential tremor as well as dystonia may 
be accompanied with orofacial manifestations. 
Moreover, since the PD patients used levodopa 
and/or dopamine agonists, therefore the orofacial 
dyskinesia could be a normal symptom of dose-
related side effects of these dopaminergic 
compounds. Levodopa-induced dyskinesia has been 
proposed to be related to oxidative stress caused by 
toxicity which leads to degeneration of striatal indirect 
pathway of medium sized spiny neurons (Loonen and 
Ivanova, 2013). This neurotoxicity could have other 
underlying genetic causes than dose-dependent 
dopamine receptor stimulation. 
Conclusion 
In conclusion, the studied variants of dopamine and 
5-hydroxytryptamine receptor genes may not 
contribute to the development of LID.  However, they 
may be related to orofacial dyskinesia via a different 
mechanism. The exact role of these neurotransmitter 
receptors in the pathogenesis of the orofacial 
 







LID 1-4 5-7 1-7 
rs3758653 DRD4 +  + +   
rs4911871 HTR2C +   +   
rs2134655 DRD3    +   
rs963468 DRD3      + 
1-4 items represent the sum of the first four parameters on the AIMS used for assessment of orofacial dyskinesia 
(these parameters include facial expressions and mouth area); 5-7 items represent the sum of 5-7 parameters  to the 
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dyskinesia remains to be elucidated. 
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